Research ExplorerPublicationsLong-term outcome, survival and predictors of mortality afte...

Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry

Standard

Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. / Kalbacher, Daniel; Schäfer, Ulrich; V Bardeleben, R Stephan; Eggebrecht, Holger; Sievert, Horst; Nickenig, Georg; Butter, Christian; May, Andreas E; Bekeredjian, Raffi; Ouarrak, Taoufik; Kuck, Karl-Heinz; Plicht, Björn; Zahn, Ralf; Baldus, Stephan; Ince, Hüseyin; Schillinger, Wolfgang; Boekstegers, Peter; Senges, Jochen; Lubos, Edith.

In: INT J CARDIOL, Vol. 277, 15.02.2019, p. 35-41.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kalbacher, D, Schäfer, U, V Bardeleben, RS, Eggebrecht, H, Sievert, H, Nickenig, G, Butter, C, May, AE, Bekeredjian, R, Ouarrak, T, Kuck, K-H, Plicht, B, Zahn, R, Baldus, S, Ince, H, Schillinger, W, Boekstegers, P, Senges, J & Lubos, E 2019, 'Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry', INT J CARDIOL, vol. 277, pp. 35-41. https://doi.org/10.1016/j.ijcard.2018.08.023

APA

Kalbacher, D., Schäfer, U., V Bardeleben, R. S., Eggebrecht, H., Sievert, H., Nickenig, G., Butter, C., May, A. E., Bekeredjian, R., Ouarrak, T., Kuck, K-H., Plicht, B., Zahn, R., Baldus, S., Ince, H., Schillinger, W., Boekstegers, P., Senges, J., & Lubos, E. (2019). Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. INT J CARDIOL, 277, 35-41. https://doi.org/10.1016/j.ijcard.2018.08.023

Vancouver

Kalbacher D, Schäfer U, V Bardeleben RS, Eggebrecht H, Sievert H, Nickenig G et al. Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. INT J CARDIOL. 2019 Feb 15;277:35-41. https://doi.org/10.1016/j.ijcard.2018.08.023

Bibtex

@article{9418f89514864e6682658167172fd547,
title = "Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry",
abstract = "BACKGROUND: MitraClip therapy is increasingly used in patients deemed inoperable to treat severe mitral regurgitation (MR), but long-tern data is scarce.AIMS: The multicentre, industry-independent German Transcatheter Mitral Valve Interventions (TRAMI) registry comprises the largest prospectively enrolled cohort of patients treated by MitraClip therapy. The current analysis is focusing on long-term mortality rates, cardiac rehospitalization and reintervention.METHODS AND RESULTS: Long-term follow-up (median time 1037 days) in the TRAMI registry was available for 722 patients treated at 20 German centres. Improvements in New York Heart Association (NYHA) functional class (I/II long-term: 65% vs. 1-year follow-up: 63.3%) and self-rated health-status (EuroQuol visual analogue scale [EQ VAS] long-term: 60 [50-70] vs. 1-year follow-up: 60 [50; 70]) were pertained over time. Estimated mortality rates by Kaplan-Meier method were 19.7% for 1-year, 31.9% for 2-year and 53.1% for 4-year follow-up without differences found for MR aetiology. Multivariable Cox-regression analysis identified previous aortic valve implantation (hazard ratio [HR] = 2.21; p < 0.0001), NYHA class IV (HR = 1.78; p < 0.001), prior cardiac decompensation (HR = 1.63; p < 0.001), creatinine > 1.5 mg/dl (HR = 1.63; p < 0.0001) and left ventricular ejection fraction < 30% (HR = 1.60; p < 0.001) as most predictive for long-term mortality.CONCLUSIONS: Long-term outcome in the TRAMI registry confirmed lasting clinical improvements and low intervention rates. Long-term mortality was strongly influenced by cardiac and non-cardiac co-morbidities and was found comparable for both MR aetiologies.",
keywords = "Aged, Aged, 80 and over, Cohort Studies, Female, Follow-Up Studies, Germany/epidemiology, Humans, Male, Mitral Valve Insufficiency/diagnostic imaging, Mortality/trends, Predictive Value of Tests, Prospective Studies, Registries, Surgical Instruments/trends, Time Factors, Transcatheter Aortic Valve Replacement/mortality, Treatment Outcome",
author = "Daniel Kalbacher and Ulrich Sch{\"a}fer and {V Bardeleben}, {R Stephan} and Holger Eggebrecht and Horst Sievert and Georg Nickenig and Christian Butter and May, {Andreas E} and Raffi Bekeredjian and Taoufik Ouarrak and Karl-Heinz Kuck and Bj{\"o}rn Plicht and Ralf Zahn and Stephan Baldus and H{\"u}seyin Ince and Wolfgang Schillinger and Peter Boekstegers and Jochen Senges and Edith Lubos",
note = "Copyright {\textcopyright} 2018 Elsevier B.V. All rights reserved.",
year = "2019",
month = feb,
day = "15",
doi = "10.1016/j.ijcard.2018.08.023",
language = "English",
volume = "277",
pages = "35--41",
journal = "INT J CARDIOL",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry

AU - Kalbacher, Daniel

AU - Schäfer, Ulrich

AU - V Bardeleben, R Stephan

AU - Eggebrecht, Holger

AU - Sievert, Horst

AU - Nickenig, Georg

AU - Butter, Christian

AU - May, Andreas E

AU - Bekeredjian, Raffi

AU - Ouarrak, Taoufik

AU - Kuck, Karl-Heinz

AU - Plicht, Björn

AU - Zahn, Ralf

AU - Baldus, Stephan

AU - Ince, Hüseyin

AU - Schillinger, Wolfgang

AU - Boekstegers, Peter

AU - Senges, Jochen

AU - Lubos, Edith

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - BACKGROUND: MitraClip therapy is increasingly used in patients deemed inoperable to treat severe mitral regurgitation (MR), but long-tern data is scarce.AIMS: The multicentre, industry-independent German Transcatheter Mitral Valve Interventions (TRAMI) registry comprises the largest prospectively enrolled cohort of patients treated by MitraClip therapy. The current analysis is focusing on long-term mortality rates, cardiac rehospitalization and reintervention.METHODS AND RESULTS: Long-term follow-up (median time 1037 days) in the TRAMI registry was available for 722 patients treated at 20 German centres. Improvements in New York Heart Association (NYHA) functional class (I/II long-term: 65% vs. 1-year follow-up: 63.3%) and self-rated health-status (EuroQuol visual analogue scale [EQ VAS] long-term: 60 [50-70] vs. 1-year follow-up: 60 [50; 70]) were pertained over time. Estimated mortality rates by Kaplan-Meier method were 19.7% for 1-year, 31.9% for 2-year and 53.1% for 4-year follow-up without differences found for MR aetiology. Multivariable Cox-regression analysis identified previous aortic valve implantation (hazard ratio [HR] = 2.21; p < 0.0001), NYHA class IV (HR = 1.78; p < 0.001), prior cardiac decompensation (HR = 1.63; p < 0.001), creatinine > 1.5 mg/dl (HR = 1.63; p < 0.0001) and left ventricular ejection fraction < 30% (HR = 1.60; p < 0.001) as most predictive for long-term mortality.CONCLUSIONS: Long-term outcome in the TRAMI registry confirmed lasting clinical improvements and low intervention rates. Long-term mortality was strongly influenced by cardiac and non-cardiac co-morbidities and was found comparable for both MR aetiologies.

AB - BACKGROUND: MitraClip therapy is increasingly used in patients deemed inoperable to treat severe mitral regurgitation (MR), but long-tern data is scarce.AIMS: The multicentre, industry-independent German Transcatheter Mitral Valve Interventions (TRAMI) registry comprises the largest prospectively enrolled cohort of patients treated by MitraClip therapy. The current analysis is focusing on long-term mortality rates, cardiac rehospitalization and reintervention.METHODS AND RESULTS: Long-term follow-up (median time 1037 days) in the TRAMI registry was available for 722 patients treated at 20 German centres. Improvements in New York Heart Association (NYHA) functional class (I/II long-term: 65% vs. 1-year follow-up: 63.3%) and self-rated health-status (EuroQuol visual analogue scale [EQ VAS] long-term: 60 [50-70] vs. 1-year follow-up: 60 [50; 70]) were pertained over time. Estimated mortality rates by Kaplan-Meier method were 19.7% for 1-year, 31.9% for 2-year and 53.1% for 4-year follow-up without differences found for MR aetiology. Multivariable Cox-regression analysis identified previous aortic valve implantation (hazard ratio [HR] = 2.21; p < 0.0001), NYHA class IV (HR = 1.78; p < 0.001), prior cardiac decompensation (HR = 1.63; p < 0.001), creatinine > 1.5 mg/dl (HR = 1.63; p < 0.0001) and left ventricular ejection fraction < 30% (HR = 1.60; p < 0.001) as most predictive for long-term mortality.CONCLUSIONS: Long-term outcome in the TRAMI registry confirmed lasting clinical improvements and low intervention rates. Long-term mortality was strongly influenced by cardiac and non-cardiac co-morbidities and was found comparable for both MR aetiologies.

KW - Aged

KW - Aged, 80 and over

KW - Cohort Studies

KW - Female

KW - Follow-Up Studies

KW - Germany/epidemiology

KW - Humans

KW - Male

KW - Mitral Valve Insufficiency/diagnostic imaging

KW - Mortality/trends

KW - Predictive Value of Tests

KW - Prospective Studies

KW - Registries

KW - Surgical Instruments/trends

KW - Time Factors

KW - Transcatheter Aortic Valve Replacement/mortality

KW - Treatment Outcome

U2 - 10.1016/j.ijcard.2018.08.023

DO - 10.1016/j.ijcard.2018.08.023

M3 - SCORING: Journal article

C2 - 30153994

VL - 277

SP - 35

EP - 41

JO - INT J CARDIOL

JF - INT J CARDIOL

SN - 0167-5273

ER -